which is expressed in all cells of myeloid origin. Upon an increase in intracellular calcium, 5-LO translocates to the nuclear membrane, which requires the action of the membrane anchor 5-LO-activating protein [1] . This process gives rise to the formation of LTA 4 , which is converted to LTB 4 through the action of LTA 4 hydrolase [2] . LTA 4 can also be converted to LTC 4 by LTC 4 synthase and constitutes the precursor of other cysteinyl LTs named LTD 4 and LTE 4 .
Introduction
Leukotrienes (LTs) are a family of mediators known to exert a multitude of biologic effects that contribute to enhance the inflammatory response. LTs are generated from the liberation of arachidonic acid through the action of cytosolic phospholipase A 2 and 5-lipoxygenase (5-LO), ticularly neutrophils and eosinophils, whereas BLT2 is expressed ubiquitously, with increased expression in lymphoid organs [11] . The chemoattractive properties of LTB 4 as well as its proinflammatory effects are mainly mediated by the BLT1 receptor. Following binding to its receptor, an increase in Ca 2+ mobilization is observed and downstream signaling molecules are activated. LTB 4 activates several kinase cascades leading to the transcription of cytokine genes. Two important but distinct signaling pathways are sensitive to LTB 4 action, one leading to the translocation of nuclear factor (NF)-κB, while the other activates members of the mitogen-activated protein kinase (MAPK) family such as p38, c-JUN kinase and extracellular signal-regulated kinases 1/2, leading to the activation of the transcription factor activated protein-1 [12] [13] [14] . In addition, LTB 4 was shown to induce neutrophil activation and degranulation through its effects on the β isoform of phosphoinositide 3-kinase and the Src kinase Yes, respectively [15, 16] . LTB 4 activates the GTPase Rac and Rac-extracellular signal-regulated kinase, two signaling molecules that contribute to phagocytosis and chemotaxis [17] . These studies demonstrate that LTB 4 can influence several kinases involved in different downstream signaling pathways associated with the aforementioned biological processes. Therefore, it is not surprising that LTB 4 can exert pleiotropic actions on host cells.
LTB 4 and the Inflammatory Response
Inflammation is a complex physiological response initiated following pathogen recognition and tissue injuries. In the early phase of inflammation, activation of resident macrophages and other immune cells induces the release of cytokines and chemokines that subsequently recruit inflammatory cells to the tissue. During infection, inflammation further correlates with increased transport of pathogens and antigen-presenting cells from the infected tissue to the lymphoid organs. This gives rise to lymphocyte activation and initiation of adaptive immunity characterized by antibody production and effector cell recruitment to the site of infection.
The early phase of the immune response is characterized, as mentioned above, by the rapid recruitment of effector cells and the release of cellular mediators that trigger the onset of the immune response. In this process, LTB 4 acts as a mediator that exerts a central role on inflammatory cells through its chemoattractant properties. This LT was initially recognized as a cellular chemoattractant released from polymorphonuclear leukocytes [18] . This was based on studies showing that intravenous injections of LTB 4 in rabbits resulted in a prompt increase in blood neutrophils, and intradermal injection of LTB 4 leads to an accumulation of neutrophils at the site of injection [19] . The capacity of LTB 4 to recruit effector cells is not limited to neutrophils. The chemoattractant activity of LTB 4 was also demonstrated for monocytes, macrophages, dendritic cells, eosinophils and effector T cells [20] [21] [22] . Of potential importance, LTB 4 induces recruitment of CD4 and CD8 effector T cells as well as T helper type 1 and T helper type 2 cells to inflamed tissue [23, 24] , providing a link between innate and adaptive immune responses. Early recruitment of activated immune cells during the onset of inflammation constitutes one of the main mechanisms through which LTB 4 modulates the inflammatory process.
Following their entry into peripheral tissue, the recruited immune cells will engage in the inflammation process by secreting cytokines and chemokines, which also contribute to promote inflammation. Evidence shows that LTB 4 is active in this process and enhances the production of several inflammatory mediators such as interleukin (IL)-2 and IL-5 by T cells. LTB 4 was also found to increase the sensitivity of T lymphocytes to IL-2, a mediator essential for T cell proliferation. In fact, in vitro assays showed that lymphocytes that had been incubated with LTB 4 for 24 h were more responsive to IL-2, showing that LTB 4 increased the sensitivity of cytotoxic lymphocytes to IL-2 activation [25] . This increased activity was attributed to an upregulation of IL-2 receptor β expression, which is mostly expressed on natural killer and CD8 T cells. Similarly, LTB 4 induces rapid, dose-dependent IL-5 production in T cells [26] . These cytokines are produced by T helper type 1 and type 2 cells and together contribute to activation of the immune response, characterized by the recruitment, proliferation and activation of immune cells.
LTB 4 increases the production of IL-1 (α/β), IL-6 and chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1) in monocytes and the release of IL-8 by neutrophils. Production of IL-1 by human monocytes stimulated with lipopolysaccharide (LPS) was potentiated in LTB 4 -pretreated cells [27] . This mediator is also considered a potent inducer of chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1) secretion in monocytes [28] . Similarly, LTB 4 induces the release of chemokine (C-X-C motif) ligand 8 (IL-8) by neutrophils and potentiates IL-8 secretion in response to various stimuli [29, 30] . Overall, the role of LTB 4 in the inflammatory re-sponse can be either directly associated with the recruitment of inflammatory cells or indirectly with its capacity to induce secretion of inflammatory mediators by surrounding cells.
Being associated with various diseases, including chronic pulmonary disorders, drugs targeting LTs were developed as anti-inflammatory medications over the last 20 years [31] . Cysteinyl LT is especially suspected to play a role in asthma, and LTB 4 , being recognized as a potent chemoattractant for leukocytes, was also associated with the inflammatory response. Due to the physiological functions it exerts on cells, LTB 4 has long been considered a detrimental mediator of inflammation.
From a clinical perspective, evidence suggests that LTB 4 plays a key role in various inflammatory diseases, especially in lung diseases such as asthma or chronic obstructive pulmonary disease. Increased levels of LTB 4 have been identified in the sputum, plasma and bronchoalveolar lavage fluid of asthmatic patients [32] [33] [34] . The levels of LTB 4 were also found to be increased in the exhaled breath condensate of chronic obstructive pulmonary disease patients [35] . Since bronchial epithelial cells and lung fibroblasts are able to secrete LTB 4 , it was assumed that in these pathological conditions, LTB 4 could exacerbate inflammatory symptoms through the recruitment and accumulation of inflammatory cells in the respiratory tract along with the secretion of inflammatory cytokines. Nevertheless, new findings on the role of LTB 4 in controlling viral infection and the mechanisms associated with such effects provide new insights into the beneficial role of LTB 4 as a regulator of the innate response. 36 ] , especially with regard to LTB 4 , which was reported to exert appealing activity on innate defenses against pathogens. In fact, besides its association with the inflammatory process, several reports from the last decade highlight the involvement of LTB 4 in the activation of innate immune defense against viral infection. The first evidence of the antiviral activity of LTB 4 was demonstrated against Epstein-Barr virus (EBV) and herpes simplex type 1 virus, two viruses of the herpes family [37, 38] . In vitro treatment of EBVinfected human peripheral blood mononuclear cells with LTB 4 was found to strongly reduce the B cell growthtransforming ability of EBV as reflected by the reduced expression of Epstein-Barr nuclear antigen in infected cells. Similar results were also obtained in Vero cell cultures infected with herpes simplex type 1 virus, in which the percentage of infected cells was also affected by the addition of exogenous LTB 4 . Interestingly, in these experiments, the antiviral potency of LTB 4 was comparable to the inhibitory effect of acyclovir, a drug widely used for the treatment of herpes infection in humans [37, 38] . These initial experiments clearly demonstrated that treatment with LTB 4 can control viral infection. In addition, treatment of cell cultures with LTB 4 did not block viral entry into the cell, suggesting that it may act on intracellular components to suppress viral replication. More recently, EBV-infected cord blood cell cultures were used to show that LTB 4 contributes to suppress the B cell transformation induced by EBV [39, 40] . The authors demonstrated that inhibition of B cell proliferation by LTB 4 was associated with activation of effector T cells.
The potential role of LTB 4 in viral infection was further demonstrated in vivo in mice infected with murine cytomegalovirus (MCMV) [41] . Intravenous administration of LTB 4 to mice infected with a lethal dose of MCMV significantly reduced the mortality rate as compared to the placebo group. Body weight and temperature data were also in accordance with the survival rate of mice treated with LTB 4 . Daily LTB 4 treatment of mice infected with a sublethal dose of MCMV was also found to reduce viral loads titrated in the salivary glands of the mice. Considering that CMV reactivation can be observed in humans, especially in those receiving immunosuppressive therapies, studies aimed at evaluating the protective role of LTB 4 against viral reactivation were also performed. Using an allogenic bone marrow transplantation model, administration of LTB 4 was found to prevent MCMV reactivation in latently infected mice. LTB 4 -associated effects were confirmed in 5-LO-deficient mice infected with MCMV and in wild-type infected mice pretreated with MK-886, an inhibitor of 5-LO-activating protein. In these animals, inhibition of LT synthesis results in a significant increase in the viral load in salivary glands, supporting a role for endogenous LTB 4 in the host defense against CMV infection.
The potential efficacy of LTB 4 to activate the host defense against viral infection was also tested with influenza virus, a single-stranded RNA virus. Daily administration of LTB 4 to influenza-infected mice potentiated the reduction of lung viral loads as opposed to mice treated with a placebo [42] . Results from this study indicate that recruit- 162 ment of neutrophils to the lungs is an important event in controlling influenza infection, which correlates with a decrease in viral load and restored lung architecture. While not specifically identifying LTB 4 , another study investigating the role of LTs in acute vesicular stomatitis virus encephalitis documented the protective role of LTs in viral infection [43] . The authors demonstrated that pharmacologic or genetic inactivation of the 5-LO enzyme correlates with a higher viral titer in the brain during early phases of infection. Interestingly, other investigations suggested that impairment of LT synthesis in acquired immunodeficiency syndrome might contribute to the observed susceptibility to opportunistic infections, supporting the beneficial effects of LTs in innate defense against viruses [44, 45] . Recently, it was shown that LTs, including LTB 4 and LTC 4 , could inhibit human immunodeficiency virus type 1 (HIV-1) infection in vitro in human monocyte-derived microglia-like cells [46] . LTB 4 was demonstrated to significantly reduce viral loads in this primary cell system, suggesting a protective role in the central nervous system of HIV-infected patients.
On the other hand, it was reported that LTB 4 and LTC 4 were increased in the plasma of human T lymphotropic virus type 1-infected patients. The authors suggest that such an enhanced concentration of LTB 4 and LTC 4 could potentially contribute to the dysregulation of the immune system in neuroinflammatory disease [47] . In a second study, it was shown that human CMV infection of vascular smooth muscle cells leads to enhanced 5-LO expression, resulting in an increase in LTB 4 production [48] . This study proposed that human CMV could initiate and sustain inflammation through the control of 5-LO expression in patients with ulcerative colitis. Despite the fact that, in the specific context of infection, upregulation of the 5-LO pathway may compromise the immune response, LTB 4 is mainly associated with beneficial effects in controlling viral infections.
LTB 4 Is Involved in Antibacterial Immunity
In addition to its potential role in controlling viral infection, LTB 4 was also suggested to contribute to bacterial clearance [reviewed in 49 ] . The first evidence of the antibacterial role of LTB 4 was highlighted with the demonstration that intraperitoneal administration of LTB 4 resolves experimental bacterial peritonitis in mice [50] . The increased clearance of Salmonella typhimurium observed in these animals was proposed to occur through an enhanced bactericidal action of macrophages since this phenomenon was abrogated in animals with high susceptibility to bacterial infection. In mice deficient for the 5-LO gene, it was demonstrated that the host response to pulmonary bacterial infection was mediated by LTs. Following intratracheal Klebsiella pneumoniae challenge, a marked increase in LTs and neutrophils was observed in wild-type mice, whereas this response was impaired in knockout mice. This phenomenon correlated with a significant increase in lethality and bacteremia in LT-deficient animals as compared to wild-type mice [51] . The reduced capacity for bacterial clearance of LT-deficient mice was associated with a defect in the phagocytic activity of alveolar macrophages. Interestingly, such defects were overcome in vitro by treatment of macrophages with exogenous LTB 4 . Similar conclusions were reached in studies using mice infected with fungal and bacterial organisms and treated with LT synthesis inhibitors, such as MK-886 and A-63162, in which reduced survival rate and bacterial clearance, respectively, were observed [52, 53] . Together, these data indicate that LTs and especially LTB 4 plays a significant role in host defense against microbial pathogens.
Innate Effector Mechanisms Activated by LTB 4 to Control Bacterial and Viral Infection
Destruction of microorganisms requires the contribution of complex intracellular mechanisms such as activation of cytotoxic systems and phagocytosis. The contribution of LTs to the modulation of antimicrobial effector functions and the role of LTB 4 in antibacterial defenses have been documented [49] . Briefly, LTB 4 modulates killing of bacteria through the synthesis of the reactive oxygen intermediate, nitric oxide, and hydrogen peroxide. LTB 4 may also regulate the release of lysosomal enzymes, cytokine production and phagocytosis, which are necessary to neutralize pathogens. These mechanisms activated by LTB 4 are summarized in table 1 . Recent insights into LTB 4 -activated mechanisms to control both bacterial and viral infections are discussed in the following sections.
LTB 4 Induces Release of Antimicrobial Peptides LTB 4 -induced antimicrobial peptide synthesis has been demonstrated against a diverse range of bacteria [49] . The mechanisms underlying the antiviral activity of LTB 4 are not fully understood and remain to be characterized. However, one of the known effective strategies to fight a wide range of pathogens includes the release of antimicrobial peptides. These antimicrobial peptides are known to exert broad-spectrum activity against bacteria, fungi and enveloped viruses [54] . For instance, β-defensin is known for its antibacterial properties through its membrane disruption effect and is also effective against yeast, such as Candida albicans. Cathelicidins are thought to neutralize LPS found on bacteria. Finally, eosinophil-derived neurotoxin and its murine homologue mouse eosinophil-associated RNase are two RNases with antiviral activity against respiratory viruses [42] . In fact, secretion of antimicrobial peptides by neutrophils was found to contribute to the antiviral activities of LTB 4 against influenza virus [42] . Indeed, treatment with LTB 4 leads to a decrease in viral load associated with increased expression of antimicrobial peptides, including β-defensin-3, mouse eosinophil-associated RNase and cathelicidin-related antimicrobial peptide, in lungs of mice infected with influenza virus. In addition, neutrophils were considered to be essential in such production of antimicrobial peptides since in neutrophil-depleted mice, inability of LTB 4 to reduce lung influenza viral loads and induce production of antimicrobial peptides was observed. Similar effector mechanisms could be activated in humans since in vitro treatment of primary human neutrophils with LTB 4 also led to rapid secretion of multiple antimicrobial peptides, which was abrogated with a BLT1 receptor-specific antagonist [42, 55] .
The LTB 4 -mediated release of antimicrobial peptides was also demonstrated in infection with CMV. Treatment of CMV-infected human peripheral blood leukocytes with LTB 4 led to a reduction of viral titers, a process involving neutrophil activation and release of antimicro- 
LTB 4 Potentiates Toll-Like Receptor Signaling
An effective immune defense against viruses is initiated following recognition of the viral components by encoded pattern recognition receptors including the Tolllike receptors (TLRs) [56] . Following binding to its receptor, LTB 4 activates signaling molecules interconnected with other cellular receptors such as TLRs. In fact, MAPKand NF-κB-mediated cytokine production are signaling events common to BLT1 and TLRs. Therefore, we can assume that LTB 4 could influence the cell response to agonists recognized by TLRs. In this regard, Serezani et al. [57] have reported that LTB 4 amplifies NF-κB activation in macrophages stimulated with MyD88-dependent agonists. Macrophages isolated from 5-LO-/-mice showed reduced production of cytokines in response to LPS and peptidoglycans, in addition to reduced p65 binding activity. Similar observations were made with macrophages isolated from BLT1-/-mice, confirming the specific role of LTB 4 /BLT1 in MyD88-dependent NF-κB activation. The authors concluded that the enhanced effect induced by LTB 4 on MyD88 expression and cytokine production was mediated by the activation of Janus kinase 2/signal transducer and activator of transcription 1 signaling, suggesting the action of LTB 4 on the MyD88 pathway.
In a more recent study aiming to investigate the interactions of LTB 4 with the TLR system, it was demonstrated that potentiation of cytokine release following stimulation of neutrophils with a combination of LTB 4 and TLR ligands such as lipoteichoic acid, LPS and CpG was dependent on activation of transforming growth factor-β-activated kinase 1 (TAK1), a molecule essential to the MyD88 signaling pathway [29] . LTB 4 potentiation of cytokine secretion in neutrophils stimulated with TLR ligands was suppressed by treatment with TAK1 inhibitor and also in a transfection assay with TAK1-targeting siRNA in HEK293 cells, confirming the action of LTB 4 on TAK1 activity. An interesting aspect of the LTB 4 action on MyD88 signaling is the demonstration that TAK1 and the MAPK p38 are interconnected in LTB 4 -treated neutrophils. Indeed, pretreatment of neutrophils with TAK1 inhibitor was found to reduce levels of phosphorylated p38, indicating that activation of p38 by LTB 4 is dependent on TAK1. While not found to be essential, activation of the protein kinase IL-1 receptor-associated kinase 1 (IRAK1; IRAK1/4 complex) by LTB 4 may potentiate cytokine production by neutrophils stimulated with TLR agonists. Since the involvement of TLRs in early recognition of viral particles is crucial to control infection, the overall consequence of such effects of LTB 4 on MyD88 signaling may result in an effective innate response against several types of viruses. A proposed mechanism illustrating the potential interactions between LTB 4 and TLR signaling pathways in neutrophils is presented in figure 1 .
Contribution of TLRs to the potentiating effect of LTB 4 on neutrophils was also evaluated. Interestingly, it was demonstrated that LTB 4 differentially modulates the expression of TLRs, depending on whether they are expressed at the cell surface or within the cell [29, 58] . It appears that LTB 4 exerts no effect on expression levels of the membrane receptors TLR2 and TLR4, nor the coreceptors TLR1 and TLR6, on neutrophils. However, LTB 4 can positively upregulate expression of intracellular TLR9 (as well as TLR7/8 mRNA levels), resulting in enhanced binding activity of its ligand. Such a dichotomy remains to be explained, but one might postulate that TLR gene expression could be differentially regulated depending on the cellular origin or the stimulus involved. Together, these results confirm that LTB 4 acts on interconnected signaling molecules to optimize an effective immune response. Moreover, we must also consider that LTB 4 may interact with multiple signaling molecules from different pathways (other than MyD88-dependent pathways) to enhance the state of activation and potentiate immune defenses. This aspect remains to be explored.
Conclusion
Although prostaglandins and LTs are for the most part associated with proinflammatory effects, the studies reviewed herein support the conclusion that LTB 4 benefits the host immune defense. The triggering of the immune response with molecules interacting with the signaling cascade of the innate defense is a very appealing avenue for the development of therapeutic approaches for the treatment of various diseases including viral infections. Investigation of LTB 4 as an 'immunoregulator' is an especially attractive approach for the development of new therapeutics since the available drugs are rather limited and in some cases may present host toxicity.
LTB 4 exerts several biological activities on the immune response, including increasing phagocytosis of microorganisms by neutrophils and macrophages, enhancement Studies in humans clearly indicate that LTB 4 contributes to the regulation of the innate immune response and merits more thorough investigation. Indeed, intravenous administration of LTB 4 to humans was reported to lead to a dose-dependent plasmatic increase in α-defensins [59] . In another study performed in healthy individuals Color version available online Fig. 1 . Schematic representation illustrating the effects of LTB 4 on the TLR signaling pathway and the release of antimicrobial peptides in neutrophils. With the exception of TLR3, all TLRs lead to the engagement of the MyD88-IRAK1/4-TAK1 axis, which culminates in the activation of MAPK-mediated activated protein-1 (AP-1) production or NF-κB-mediated cytokine production. Upon ligation of LTB 4 to the BLT1 receptor (BLT1R), cellular signaling intersects with downstream TAK1, which occupies a central role in the TLR signaling cascade. In the presence of TLR agonists, LTB 4 potentiates TAK1 activation, leading to an increase in cytokine production. LTB 4 can also activate IRAK1/4, a process which is, however, dispensable to the enhancement of cytokine synthesis. LTB 4 mediates the synthesis and release of antimicrobial peptides [42, 55] through phosphoinositide 3-kinase (PI3K) and Src signaling pathways. Red arrows represent potentiating/activating effects of LTB 4 . EDN = Eosinophil-derived neurotoxin; CRAMP = cathelicidin-related antimicrobial peptide; EARS = eosinophil-associated RNase. having received nasal administration of LTB 4 , increased production of myeloperoxidase and α-defensins was detected in nasal lavage fluids. In healthy volunteers infected with rhinovirus-16 and treated with LTB 4 , reduced viral replication was measured as compared with controls [60] . The impact of LTB 4 on HIV-1-infected patients was also tested [61] . While subjects did not manifest any adverse effects over the trial period, this study failed to show anti-HIV activity. The failure to observe changes in CD4 counts and viral loads might be attributable to the selection criteria of the HIV-infected group. One could consider selecting a more advanced disease state characterized by a higher viral load and a lower CD4 count. In these conditions, subtle improvements in patient status might have been more apparent and translated into higher CD4 counts as well as a reduced viral load. In support of our hypothesis are the results from a previous phase II clinical trial conducted by Boehringer Ingelheim, in which an LTB 4 receptor BLT1 antagonist (BIIL 284 BS) was assessed in the treatment of cystic fibrosis [62] . This multicenter study showed that a significant proportion of adult and pediatric patients treated with this drug experienced adverse events involving pulmonary exacerbation and required hospitalization. The investigators proposed that the high potency of this inhibitor might explain the observed side effects, which probably resulted from a deficient antimicrobial immune response. This highlights the potential of LTB 4 in the regulation of the immune response.
Today, the challenge in the development of antiviral drugs is to design a molecule with high efficacy, low host toxicity and reduced host adverse effects. Moreover, most antiviral agents are designed to treat a specific type of viral infection and usually focus on a virus-associated component. Drugs that boost the immune system without specifically interacting with critical components of the viral life cycle should be considered. This would reduce the selective pressure of virus-associated target therapeutics and would also reduce the appearance of resistant viral strains. Although the antibacterial and antiparasitic properties of LTB 4 seem promising, the future of the potential therapeutic development of this endogenous mediator lies in its antiviral properties and its potential to highlight avenues for new drug development. In addition, we must also consider that if the use of an 'immune booster' like LTB 4 can be controlled to modulate and enhance the level of immune responsiveness, it would constitute a very powerful tool to fight against various microbial infections. LTB 4 could then be used in prophylaxis to prevent infections or in therapy to boost the physiological response against pathogens. Interestingly, this endogenous molecule in combination with other antimicrobial drugs could result in synergic activity that potentiates their therapeutic efficacy.
LTB 4 is an important player in the innate immune defense against infectious microorganisms including viruses. Its 'boosting effects' on the TLR-mediated immune response invite pursuit of the development of such related molecules for the treatment of viral infections and will also be useful in the elaboration of new therapeutic strategies acting on the potentiation of the innate immune response.
